A recent comprehensive study investigating 131 invasive urothelial bladder carcinomas identified inactivated p53 through TP53 gene mutations in 49% of tested samples, thus, highlighting its relevance in diagnosis and treatment management of bladder cancers [22]. The gene discussed is TP53; the disease is bladder transitional cell carcinoma.